Single-cell RNA sequencing uncovers an immunosuppressive program in PDAC mast cells: tumour-driven activation, proliferation, and association with Treg recruitment
Aug 2026· Annals medicus· Vol 58· 0 citations· 55 references
Medicine
TL;DR
This study suggests that MCs are key orchestrators of immunosuppression in PDAC, predicted to interact with Tregs through the MIF–CD74/CXCR4 axis, offering a novel rationale for targeting the MC–Treg axis in future immunotherapeutic strategies.
Abstract
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly immunosuppressive tumour microenvironment (TME), which contributes to its resistance to immunotherapy. Although mast cells (MCs) have been implicated in PDAC progression, their functional heterogeneity and candidate signaling models of immune modulation remain poorly understood. Methods Through an integrated analysis of multiple single-cell RNA sequencing (scRNA-seq) datasets, we identified a significant enrichment of MCs in PDAC tissues and established a characteristic gene signature (TPSAB1, TPSB2, CPA3, HPGDS, KIT, LTC4S) for their precise identification. Results Single-cell RNA-seq analysis categorized MCs in PDAC into resting, activated, and proliferating subpopulations. To functionally validate these transcriptomic predictions, in vitro co-culture experiments showed that pancreatic cancer cells promote the activation and proliferation of MCs. Cell–cell communication analysis suggested that activated MCs preferentially interact with regulatory T cells (Tregs) via the MIF–(CD74/CXCR4) signaling axis. This interaction was associated with an immunosuppressive T-cell landscape, characterized by an expanded population of Tregs exhibiting a highly activated immunosuppressive phenotype. Spatial transcriptomics and immunofluorescence validated the confirmed the spatial proximity of MCs and Tregs in PDAC tissues. Clinically, high expression of MC-Treg signature genes correlated with poor patient survival. Conclusions Our study suggests that MCs are key orchestrators of immunosuppression in PDAC, predicted to interact with Tregs through the MIF–CD74/CXCR4 axis, offering a novel rationale for targeting the MC–Treg axis in future immunotherapeutic strategies.
These findings identify a tumor-adapted MC state that orchestrates immune evasion and tissue remodeling during CRC progression, supporting the notion that MC are reprogrammed toward an immune-suppressive and pro-tumorigenic phenotype.
E. Putro, Alessia Carnevale, Caterina Marangio et al.· Cell Death & Disease· 0 citations
Pancreatic stellate cells (PSCs) are a principal source of cancer-associated fibroblasts (CAF) in pancreatic ductal adenocarcinoma (PDAC), yet the mechanisms that convert tumor-derived inflammatory cues into a persistent, CAF-like state remain poorly defined. We previously identified tumor cell-intrinsic p38α MAP...
Sayan Chakraborty, Camille Acevedo, Samara P. Singh et al.· Cancer Research· 0 citations
Long non-coding RNAs (lncRNAs) are critical regulators of the tumor microenvironment (TME); however, their cell-specific roles in predicting immunotherapy response in breast cancer (BC) remain poorly understood. This study aimed to identify immune cell-specific lncRNA signatures associated with potential pembrolizumab...
Clayton Voidelo, Thalita Maria Do Nascimento, R. D. da Cunha et al.· International Journal of Mol...· 0 citations
A comprehensive single-cell multiomic analysis of primary human T cells exposed to exosomes derived from 17 genomically diverse TNBC cell lines and 35 patient samples uncovered conserved and subtype-specific immunomodulatory programs induced by TNBC exosomes.
Sanam Rezaei Benam, S. Maleknia, Kent Williams et al.· Signal Transduction and Targ...· 0 citations
The HCC TIME is profoundly immunosuppressive, driven by myeloid dominance and multi-checkpoint T cell exhaustion, providing direct mechanistic rationale for combining macrophage reprogramming, dual checkpoint blockade, and anti-angiogenic strategies with SBRT.
Xiao-Fei Zhang, Xiao-Han Ma, Sheng Chen et al.· Frontiers in Cell and Develo...· 0 citations